AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study

Trial Profile

AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2017

At a glance

  • Drugs Esketamine (Primary)
  • Indications Tinnitus
  • Focus Adverse reactions; Registrational
  • Acronyms AMPACT1
  • Sponsors Auris Medical
  • Most Recent Events

    • 09 May 2017 According to an Auris Medical media release, this is the second of two open-label extension studies with Keyzilen that were conducted in response to a request from the US Food and Drug Administration (FDA) for safety data from chronic intermittent use of Keyzilen for up to 12 months.
    • 09 May 2017 Results published in an Auris Medical Media Release
    • 24 Apr 2017 According to an Auris Medical media release, results from this trial are expected later this quarter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top